NANOGEN INC. in den Startlöchern - 500 Beiträge pro Seite

[gerdass]

Internationale Handelsplätze
NASDAQ
NGEN / USD 0,79
2.000 +0,060
+8,22 22:00:05
01.10.2007 -
- 0,73
0,79 0,83
0,77 296.743
238.139

[vvogel]

Antwort auf Beitrag Nr.: 31.811.983 von gerdass am 02.10.07 00:59:45

Nanogen hat gute Produkte und jede Menge Patente - in Anbetracht
dessen ist der Kurs ein Witz.

Leider schaffen sie es nicht, die PS auf die Straße zu bringen.

Ist nur eine Frage der Zeit, bis sie von einem Pharma- oder
Biotechnologie-Unternehmen aufgekauft werden ...

[gerdass]

Antwort auf Beitrag Nr.: 31.814.382 von vvogel am 02.10.07 10:58:27

Schon erstaunlich wie weit du denkst
ich sehe es allerdings fast auch genau so

[Magnetfeldfredy]

Antwort auf Beitrag Nr.: 31.814.382 von vvogel am 02.10.07 10:58:27

Daß seh ich leider anders, ich trade NGEN schon seit ca. 2000! und hatte viel Hoffnung in den Patenten etc. aber die machen jedes Qartal mehr Verlust als Gewinn und wenn nur Irgendeines der Patente wertvoll wäre, hätte man NGEN schon längst übernommen.
Hier droht leider der Totalverlust!

[FRAGERO]

Antwort auf Beitrag Nr.: 31.830.634 von Magnetfeldfredy am 03.10.07 14:41:59

Richtig !!!!

Jetzt noch schnellstens aussteigen, wer überhaupt noch hier investiert sein sollte;

es wird da wohl eh nur noch eine handvoll von Lemmingen geben, seit den heutigen, späten Abendstunden.....!!!


Fragero

[FRAGERO]

Antwort auf Beitrag Nr.: 31.830.634 von Magnetfeldfredy am 03.10.07 14:41:59

falsches Grammatik: in d e n Patenten
sondern vielmehr richtiggehend: in d i e Patente

Fragero

[Honke69]

Antwort auf Beitrag Nr.: 33.636.754 von FRAGERO am 13.03.08 23:04:59

Bin schon länger draussen und schau mir die Sache von der Seitenlinie an.

Stärkstes Ausstiegsargument war die Dollarschwindsucht. Es ist zu vermuten, dass das noch bis hin zu einem € / $ - Verhältnis von 1 zu 2 laufen wird (aktuell 1 zu 1,56).

Erst wenn von der Seite Entspannung eintritt bin ich wieder bei euch.

[OJS]

DRI Capital Inc. Acquires Royalties from Nanogen Inc. for US$10 Million
DRI Capital Inc. (DRI) and Nanogen, Inc. (Nasdaq:NGEN) announced today that they have entered into an agreement for DRI to acquire, for US$10 million, all future royalties generated by Applied Biosystems (ABI) under a license ABI has taken from Nanogen for MGB™ (minor groove binder) technology.

“This transaction extends DRI’s interests in royalties related to molecular biology research tools,” said Joshua Salisbury, Managing Director at DRI. “This agreement is another example of the tailored and innovative sources of capital DRI offers and we are pleased that we were able to work with Nanogen again.”

“Monetizing this royalty stream provides us with a non-dilutive means of raising capital to fund our operations as we work towards achieving cash flow breakeven in late 2008,” said Howard C. Birndorf, Nanogen chairman and chief executive officer.

The royalty payments included in the agreement are related to Nanogen’s patented MGB™ technology that has been licensed to ABI for use in ABI’s TaqMan® products (TaqMan® is a registered trademark of Roche Molecular Systems, Inc.). ABI’s TaqMan® assays library using Nanogen’s MGB™ is the leading life science research product library for PCR applications. Nanogen’s MGB™ technology provides many advantages in the design of oligonucleotide probes, and has become a sought after component for many companies working in the molecular detection and diagnostic marketplace. Nanogen has an active partnering and licensing program and has more than 40 patents related to nucleic acid detection.

About DRI Capital

DRI Capital is a privately held investment management company, focused on the healthcare industry, with over US$1 billion under management. DRI Capital currently manages two funds: the Royalty Monetization Fund and the Structured Finance Fund.

The Royalty Monetization Fund acquires existing royalty streams at competitive rates from companies, institutions and inventors. DRI Capital is a leader in monetizing royalties, having acquired over US$850 million in royalty-based cash flows on commercialized products. In 2007 alone, DRI Capital has deployed about US$450 million with royalty acquisitions on products such as Enbrel, Flumist, Preotact and PEG-INTRON.

The Structured Finance Fund, launched in January 2008 with approximately US$300 million, is a hybrid debt and equity fund which invests in commercial stage healthcare products through investments in synthetic royalties, debt, and structured debt/equity instruments. The fund focuses on commercial stage pharmaceuticals and medical devices and is not limited to a therapeutic category or market segment. The financing that the Structured Finance Fund provides, which is primarily non-dilutive, allows for companies to finance in-licensing and new product acquisitions, sales force expansions, or fund additional capital needs.

www.dricapital.com

About Nanogen, Inc.

Nanogen (Nasdaq: NGEN - News) has a strong product and proprietary technology base of diagnostic solutions for two of the fastest growing in vitro diagnostic (IVD) markets—molecular diagnostics and rapid point-of-care testing. The company provides their innovative, high-quality diagnostic products to clinicians and physicians worldwide, making it easier to predict and diagnose diseases, ultimately improving patient care. Products include molecular diagnostic kits and reagents, and kits for rapid, point-of-care testing. Nanogen has pioneered research in areas involving biomedical markers, molecular biology and nanotechnology to bring better results to diagnostics and healthcare. For additional information please visit Nanogen’s website at www.nanogen.com.

Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. Actual results may differ materially from these forward-looking statements due to a number of factors and, consequently, you should not rely on such forward looking statement as prediction of future event. These factors include, but are not limited to, the Company’s ability to achieve cash flow breakeven, ability to obtain financing, its ability to comply with the terms of its outstanding indebtedness, ability to remain listed on the NASDAQ Global Market, whether patents owned or licensed by the Company will be developed into products, whether the patents owned by Company offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption “Risk Factors” in the Company’s Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.

Nanogen, Inc.
Nick Venuto, CFO
858-410-4600
[e-mail]
or
DRI Capital
Joshua Salisbury, Managing Director, Healthcare Funds
416-324-5712
[e-mail]



Source: Business Wire (March 31, 2008 - 7:45 AM EDT)

News by QuoteMedia
www.quotemedia.com

[dongabor]

Ts.., ts..., ts...

Kaum passt ma net auf, wird a alter Thread
reaktiviert und da weitergepostet.

War Euch der letzte ned gut genug ?


lG.
dg.

(letzte Lemming, geht dann mit der "Pumpie" durch
und macht die Lichter aus.)

[OJS]

Antwort auf Beitrag Nr.: 33.778.015 von dongabor am 01.04.08 15:22:31

... einen haben wir noch ...

Nanogen and Thermo Fisher Scientific Partner to Provide Molecular-Biology Products to Research Market
Nanogen, Inc. (Nasdaq:NGEN), developer of molecular-biology and rapid diagnostic products, and Thermo Fisher Scientific Inc., the world leader in serving science, have entered into an agreement in which Thermo Fisher will be the exclusive provider of a variety of products used in gene-expression experiments. These products are based on Nanogen’s second generation proprietary probe technology for real-time PCR (polymerase chain reaction) applications, the most widely used method for the amplification and measurement of DNA and RNA for molecular diagnostics and life science research.

The agreement covers both custom and standard catalog products based on Nanogen’s technology for real-time PCR applications. This probe technology is used as a method of quantitative detection for specific DNA or RNA sequences in a biological sample and incorporates Nanogen’s MGB (Minor Groove Binder) technology. The Minor Groove Binder is a crescent-shaped molecule that when coupled to an oligonucleotide probe stabilizes the detection-target duplex, improving efficiency and specificity compared to longer traditional probes.

“We’re very excited to partner with Thermo Fisher Scientific for our probe technology,” said Howard Birndorf, CEO of Nanogen. “Our proprietary probe technology has proven to provide better results than traditional PCR probe technology. We’re proud to serve the rapidly growing needs of the research market through partners like Thermo Fisher, which can help researchers advance basic biology and develop new therapeutics.”

David Eansor, president of the Life Science Research business at Thermo Fisher Scientific, added, “We are delighted to add Nanogen’s Probe technology to our extensive range of genomic-analysis tools. The resulting products will complement our offering of gene-expression modulation tools, PCR reagents, plastics and instruments, creating a more complete genomic workflow solution for our customers.”

Nanogen’s MGB technology is licensed broadly in various fields and is now an integral component in thousands of PCR probe products. Nanogen has more than 35 reagent and kit products that are sold for clinical diagnostic use under the MGB Alert® and Q-PCR Alert™ brands.

About Nanogen, Inc.

Nanogen (Nasdaq:NGEN) has a strong product and proprietary technology base of diagnostic solutions for two of the fastest growing in vitro diagnostic (IVD) markets—molecular diagnostics and rapid point-of-care testing. The company provides their innovative, high-quality diagnostic products to clinicians and physicians worldwide, making it easier to predict and diagnose diseases, ultimately improving patient care. Products include molecular diagnostic kits and reagents, and kits for rapid, point-of-care testing. Nanogen has pioneered research in areas involving biomedical markers, molecular biology and nanotechnology to bring better results to diagnostics and healthcare. For additional information please visit Nanogen’s website at www.nanogen.com.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE:TMO) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With annual revenues of $10 billion, we have more than 30,000 employees and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit www.thermofisher.com.

Nanogen Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen’s Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.

Nanogen, Inc.
Nicholas Venuto, Chief Financial Officer, 858-410-4600
or
Kelly Gann, Marketing Communications, 858-410-4667
[e-mail]



Source: Business Wire (April 2, 2008 - 7:07 AM EDT)

News by QuoteMedia
www.quotemedia.com

[moz01]

Dutton Associates Announces Investment Opinion: Nanogen Strong Speculative Buy Rating In Update Coverage By Dutton Associates


EL DORADO HILLS, Calif., Apr 22, 2008 (BUSINESS WIRE) -- Dutton Associates updates its coverage of Nanogen (Nasdaq:NGEN) maintaining a Strong Speculative Buy rating and a $1.00 price target. The 13-page report by Dutton senior analyst Wayne T. Lottinville, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals.
Nanogen's business is in vitro diagnostic testing. Its mission is to make the detection, diagnosis, and treatment and monitoring of an individual's health easier and faster. Nanogen is currently developing products for two major diagnostic markets: molecular and point-of-care. The molecular diagnostic market is about $2.5 billion a year with a projected 15 percent annual growth rate. Rapid point-of-care diagnostics make up a $2 billion market. Within these two markets, Nanogen offers advanced in vitro diagnostic tests for infectious diseases and cardiac testing. We believe that investors are only now discovering the "new" Nanogen. The Company recently discontinued one of its three product lines and is focusing on products and opportunities it acquired in the past four years. These acquisitions are already producing a positive effect on the Company's bottom line. Only recently has this turnaround begun to be recognized and understood by Wall Street. We believe that the "new" Nanogen has solid market opportunities before it and has the managerial wherewithal to capitalize on those opportunities. Revenues should reach $48 million in 2008, rising to $58 million in 2009, with loss per share decreasing to $(.28) in 2008 and $(.09) in 2009.

About Dutton Associates

Dutton Associates is one of the largest independent investment research firms in the U.S. Its 30 senior analysts are primarily CFAs, and have expertise in many industries. Dutton & Associates provides continuing analyst coverage of over 140 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors.

The cost of enrollment in our one-year continuing research program is US $35,000 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. Dutton Associates received $35,000 from the Company for 4 Research Reports with coverage commencing on 2/22/2008. We do not accept payment of our fees in company stock. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.

SOURCE: Nanogen



CONTACT: Dutton Associates
John M. Dutton, President, 916/960-0623

Copyright Business Wire 2008
-0-

KEYWORD: United States
North America
California
INDUSTRY KEYWORD: Health
Other Health

[kardoss12]

Antwort auf Beitrag Nr.: 33.943.315 von moz01 am 22.04.08 16:10:33

Nanogen Ziel- erste Einschätzung 1 USD

[Tiefstseetaucher]

Die letzten Quartalszahlen scheinen vom Markt nun doch eher negativ aufgenommen zu werden. Es sieht alles andere als gut aus, egal welche Kursziele Dutton Associates noch angibt. Schaun wir mal, wann hier die Lichter ganz ausgehen.



Gruß

Tiefstseetaucher

[dongabor]

Antwort auf Beitrag Nr.: 34.103.758 von Tiefstseetaucher am 15.05.08 19:07:56

Wie schon des öfteren erwähnt:

Ich bin dat letzte Lemmingchen, welche noch shares hortet.
Aber die Pumpie ist schon gut geölt, aufmagaziniert
und durchgeladen bis zum geht nich mehr.

Und dann gehen bei denen die Lichter nicht lediglich aus !

Oh nein, dann komm icke, und verschrote die letzten Lämpchen
und wenn zufällig dem CEO sein Luxusbody auch noch im Weg steht -
na was soll's - komm ja schliesslich aus Austria.
Da versteht man mit solchen Dingen umzugehen.

Wenn ich zu besoffen bin um gut genug zu zielen -
auch kein Malheur - die haben sicher noch genügend
Kellerlokale unter den Büros und dann verschwinden
halt wieder ein paar top-employees auf ein paar Jahre.


dongabor